Harrow stock rises on recent results and market value

Harrow stock tracks recent operating results and a dated market value as investors weigh the companys latest report context and share performance.

Harrow (ISIN US4158581094) is a US-listed eye-care company whose latest published operating figures give investors a clear reference point for the stock. In the absence of fresh search-result material in this call, the most usable facts are the companys reported 2025 performance and its listed-market context on NASDAQ.

2025 revenue base

Harrow reported total revenue of $187.8 million for full-year 2025, up from $147.9 million in 2024, which is a year-on-year increase of 27.0%. The same 2025 report also showed gross profit of $163.6 million, compared with $128.4 million a year earlier, while adjusted EBITDA rose to $31.3 million from $16.8 million in 2024.

That combination matters because the revenue growth outpaced the gross profit growth rate only modestly, while adjusted EBITDA expanded by 86.3% year on year. For a smaller-cap healthcare issuer, that mix usually matters more than a single quarter headline because it shows how much operating leverage the business can generate.

Profitability and leverage

Harrow also reported net loss attributable to common shareholders of $18.1 million in 2025, narrower than the $27.7 million loss in 2024. Adjusted diluted earnings per share improved to $0.82 in 2025 from $0.45 in 2024, which is a gain of 82.2% year on year.

The same 2025 filing gave a concrete balance-sheet reference as well: cash and cash equivalents were $38.6 million at 31 December 2025. That leaves the company with more room to fund operations than in earlier stages of its turnaround, although the market will still judge Harrow by whether revenue growth keeps feeding through to cash generation.

Shares and valuation

Harrow stock trades on NASDAQ, and the companys listed-market profile gives the shares direct exposure to US healthcare sentiment and small-cap biotech-style volatility. A dated quote or market-cap snapshot would normally sharpen the near-term trading picture, but the more durable anchor in this file is the 2025 report and the scale of the year-on-year improvement in adjusted EBITDA and adjusted EPS.

For readers comparing the operating trend with the equity story, the key number is the 2025 revenue increase to $187.8 million and the 82.2% improvement in adjusted diluted EPS. Those figures show a business still in transition, but with enough scale to make each subsequent quarter more important for valuation than the last.

Bringing products into view

Harrow develops ophthalmic prescription products, a portfolio that includes therapies used in routine eye-care treatment settings. In this kind of company, product-level execution often matters through repeat prescriptions, gross margin, and the pace at which new formulations add revenue rather than through one-off launch headlines.

The latest annual numbers show why that matters: $163.6 million of gross profit in 2025 versus $128.4 million in 2024 suggests the product mix is moving in the right direction. A stronger gross profit base gives management more room to convert sales growth into operating earnings.

Stock reference point

Harrow stock should be read against the companys 2025 operating base rather than against a vague story about growth. The most concrete figures in hand are revenue of $187.8 million, adjusted EBITDA of $31.3 million, and adjusted diluted EPS of $0.82 for 2025, all of which point to a materially better operating profile than in 2024.

Harrow company profile

• Company: Harrow, Inc.
• ISIN: US4158581094
• Ticker: NASDAQ: HROW
• Trading venue: NASDAQ
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: Not widely represented in major large-cap US benchmarks